1. Founded on Sep. 27, 2004, OK Biotech Corporation is mainly engaged in manufacture and sale of blood glucose testing machine for home health care use and disposable blood glucose testing chip. It issued its stock on Oct. 14, 2010 and landed on GreTai on Dec. 30, 2010. 2. business class and background: A. the main controller is chairman & General Manager Lai Jia De. Other directors are mostly managers of OK Biotech Corporation, such as Manufacturing Department Manager Zhang De Quan, Assistant of General Manager Wang De Zhao, and Business Department Manager Wang Xiu Qin. Other director is Zhang De Cheng. B. 3 Supervisors are respectively Chen Zhen Mu, He Li Fen and Lin Zhen Cheng. 3. Operational Highlights: major revenue comes from blood glucose testing chip which accounts for 80% . And 20% of the revenue comes from the blood glucose testing machine, etc. They are mostly used for testing blood glucose of the diabetics. B. Major revenue comes from America, accounting for 90%. In 2009, the sales were too centralized. The sales volume to one company reached 89%. C. In the blood glucose testing market. The main suppliers are Roche, Johnson&Johnson, Bayer and Abbott. The market share of Taiwan factories is still very low. In Taiwan, the competitors are Wuding, Huaguang, and Taibo.
Headquarters
No. 91, Sec. 2, Gongdao 5Th Rd
Hsinchu City; Hsinchu City;
Contact Details: Purchase the OK Biotech Co., Ltd. report to view the information.
Website: http://www.okbiotech.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service